Answers are grounded in this paper and cite their sources.
Cryptococcus remains the most common cause of adult meningitis in Africa and the second leading cause of AIDS-related mortality after tuberculosis [1,2]. The past 20 years have seen significant progress in the treatment of HIV-associated cryptococcal meningitis: shorter amphotericin B-based induction treatments in combination with flucytosine and fluconazole have resulted in a substantial survival benefit[3,4]. As a result, access to, and implementation of, these regimens has been a focus for successful advocacy efforts [5,6]. In addition to effective antifungal therapy, management of raised intracranial pressure (ICP), a common complication of cryptococcal meningitis, is a core component of care included in the World Health Organization (WHO) guidelines on the management of cryptococcal disease in people living with HIV [7]
No takes yet. Share an insight, caveat, or question.
Falconer et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: